Skip to main content
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology 9/2009

01.09.2009 | Pathology

Amyloid precursor protein processing and retinal pathology in mouse models of Alzheimer’s disease

verfasst von: R. Michael Dutescu, Qiao-Xin Li, Jonathan Crowston, Colin L. Masters, Paul N. Baird, Janetta G. Culvenor

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 9/2009

Einloggen, um Zugang zu erhalten

Abstract

Background

Retinal ganglion cell loss is considered to be a cause of visual impairment in Alzheimer`s patients. Alterations in amyloid precursor protein (APP) processing and amyloid-β (Aβ) accumulation, key molecules associated with Alzheimer`s disease pathogenesis, may therefore contribute to retinal damage. We therefore investigated retinal APP processing and eye morphology in Alzheimer`s transgenic mouse models.

Methods

Eyes and brain samples of 2- to 18-month-old transgenic mice expressing human APP with the double Swedish mutation (APPswe) (APP K595N/M596L)(Tg2576) were compared with eyes and brain tissue from wild-type background C57BL6xSJL controls. In addition, 6- to 12-month-old double transgenic mice over-expressing human APPswe and mutant presenilin 1 with exon 9 deletion (APPswe/PS1-dE9) were compared with background controls of C57BL6xC3H strain. Tissue samples were fixed in formalin for immunohistochemistry, and dissected retinal and cerebellar extracts were frozen for Western blotting and enzyme-linked immunosorbent assay (ELISA). Monoclonal antibodies 1E8 and WO2 were used for immunohistochemical detection of APP and Aβ, whereas Aβ 42/40 levels were assayed by ELISA. APP and processed fragments were detected biochemically by Western blotting with domain-specific antibodies, using antibody WO2 (Aβ) and rabbit antibody 369 to the C-terminal domain of APP.

Results

Immunocytochemistry revealed strong cytoplasmic expression of APP and possibly Aβ in retinal ganglion cells and inner nuclear layer cells, and in lens and corneal epithelia for APP transgenic mice. Retinas from the APP transgenic mouse strains contained 18 to 70 kDa APP proteolytic products that were not detected in the cerebellum. We found a higher proportion of APP α-secretase generated C-terminal fragments in transgenic retinal tissues than β-secretase-generated C-terminal fragments. Very low level Aβ was detected in transgenic retinas by ELISA; retinal Aβ 42 was 75 times less than for transgenic brain. Aβ was not detected in mouse retina by Western blotting in our study, indicating much less generation of Aβ in retina than brain tissue.

Conclusions

Alzheimer’s mouse model retinas present with different APP proteolytic products and have a significantly lower production of amyloidogenic Aβ than found in brain.
Literatur
1.
Zurück zum Zitat Mendez MF, Mendez MA, Martin R, Smyth KA, Whitehouse PJ (1990) Complex visual disturbances in Alzheimer’s disease. Neurology 40:439–443PubMed Mendez MF, Mendez MA, Martin R, Smyth KA, Whitehouse PJ (1990) Complex visual disturbances in Alzheimer’s disease. Neurology 40:439–443PubMed
2.
Zurück zum Zitat Tippett WJ, Krajewski A, Sergio LE (2007) Visuomotor integration is compromised in Alzheimer’s disease patients reaching for remembered targets. Eur Neurol 58:1–114. doi:10.1159/000102160 PubMedCrossRef Tippett WJ, Krajewski A, Sergio LE (2007) Visuomotor integration is compromised in Alzheimer’s disease patients reaching for remembered targets. Eur Neurol 58:1–114. doi:10.​1159/​000102160 PubMedCrossRef
3.
Zurück zum Zitat Gary (1989) Abnormal pattern electroretinograms in patients with sede dementia of the alzheimer type. Ann Neurol 26:226–231CrossRef Gary (1989) Abnormal pattern electroretinograms in patients with sede dementia of the alzheimer type. Ann Neurol 26:226–231CrossRef
5.
Zurück zum Zitat Ojima T, Tanabe T, Hangai M, Yu S, Morishita S, Yoshimura N (2007) Measurement of retinal nerve fiber layer thickness and macular volume for glaucoma detection using optical coherence tomography. Jpn J Ophthalmol 51:197–203. doi:10.1007/s10384–006-0433-y PubMedCrossRef Ojima T, Tanabe T, Hangai M, Yu S, Morishita S, Yoshimura N (2007) Measurement of retinal nerve fiber layer thickness and macular volume for glaucoma detection using optical coherence tomography. Jpn J Ophthalmol 51:197–203. doi:10.​1007/​s10384–006-0433-y PubMedCrossRef
6.
7.
Zurück zum Zitat Syed AB, Armstrong RA, Smith CU (2005) A quantitative analysis of optic nerve axons in elderly control subjects and patients with Alzheimer’s disease. Folia Neuropathol 43:1–69PubMed Syed AB, Armstrong RA, Smith CU (2005) A quantitative analysis of optic nerve axons in elderly control subjects and patients with Alzheimer’s disease. Folia Neuropathol 43:1–69PubMed
9.
Zurück zum Zitat Hanger DP, Brion JP, Gallo JM, Cairns NJ, Luthert PJ, Anderton BH (1991) Tau in Alzheimer’s disease and Down’s syndrome is insoluble and abnormally phosphorylated. Biochem J 275(Pt 1):99–104PubMed Hanger DP, Brion JP, Gallo JM, Cairns NJ, Luthert PJ, Anderton BH (1991) Tau in Alzheimer’s disease and Down’s syndrome is insoluble and abnormally phosphorylated. Biochem J 275(Pt 1):99–104PubMed
13.
Zurück zum Zitat Yoshida T, Ohno-Matsui K, Ichinose S, Sato T, Iwata N, Saido TC, Hisatomi T, Mochizuki M, Morita I (2005) The potential role of amyloid beta in the pathogenesis of age-related macular degeneration. J Clin Invest 115:2793–2800. doi:10.1172/JCI24635 PubMedCrossRef Yoshida T, Ohno-Matsui K, Ichinose S, Sato T, Iwata N, Saido TC, Hisatomi T, Mochizuki M, Morita I (2005) The potential role of amyloid beta in the pathogenesis of age-related macular degeneration. J Clin Invest 115:2793–2800. doi:10.​1172/​JCI24635 PubMedCrossRef
14.
Zurück zum Zitat Goldstein LE, Muffat JA, Cherny RA, Moir RD, Ericsson MH, Huang X, Mavros C, Coccia JA, Faget KY, Fitch KA, Masters CL, Tanzi RE, Chylack LT Jr, Bush AI (2003) Cytosolic beta-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer’s disease. Lancet 361:1258–1265. doi:10.1016/S0140-6736(03)12981-9 PubMedCrossRef Goldstein LE, Muffat JA, Cherny RA, Moir RD, Ericsson MH, Huang X, Mavros C, Coccia JA, Faget KY, Fitch KA, Masters CL, Tanzi RE, Chylack LT Jr, Bush AI (2003) Cytosolic beta-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer’s disease. Lancet 361:1258–1265. doi:10.​1016/​S0140-6736(03)12981-9 PubMedCrossRef
15.
Zurück zum Zitat Guo L, Salt TE, Luong V, Wood N, Cheung W, Maass A, Ferrari G, Russo-Marie F, Sillito AM, Cheetham ME, Moss SE, Fitzke FW, Cordeiro MF (2007) Targeting amyloid-beta in glaucoma treatment. Proc Natl Acad Sci USA 104:13444–13449. doi:10.1073/pnas.0703707104 PubMedCrossRef Guo L, Salt TE, Luong V, Wood N, Cheung W, Maass A, Ferrari G, Russo-Marie F, Sillito AM, Cheetham ME, Moss SE, Fitzke FW, Cordeiro MF (2007) Targeting amyloid-beta in glaucoma treatment. Proc Natl Acad Sci USA 104:13444–13449. doi:10.​1073/​pnas.​0703707104 PubMedCrossRef
16.
Zurück zum Zitat Goldblum D, Kipfer-Kauer A, Sarra GM, Wolf S, Frueh BE (2007) Distribution of amyloid precursor protein and amyloid-beta immunoreactivity in DBA/2J glaucomatous mouse retinas. Invest Ophthalmol Vis Sci 48:5085–5090. doi:10.1167/iovs.06-1249 PubMedCrossRef Goldblum D, Kipfer-Kauer A, Sarra GM, Wolf S, Frueh BE (2007) Distribution of amyloid precursor protein and amyloid-beta immunoreactivity in DBA/2J glaucomatous mouse retinas. Invest Ophthalmol Vis Sci 48:5085–5090. doi:10.​1167/​iovs.​06-1249 PubMedCrossRef
17.
Zurück zum Zitat Haass C, Lemere CA, Capell A, Citron M, Seubert P, Schenk D, Lannfelt L, Selkoe DJ (1995) The Swedish mutation causes early-onset Alzheimer’s disease by beta-secretase cleavage within the secretory pathway. Nat Med 1:1291–1296. doi:10.1038/nm1295-1291 PubMedCrossRef Haass C, Lemere CA, Capell A, Citron M, Seubert P, Schenk D, Lannfelt L, Selkoe DJ (1995) The Swedish mutation causes early-onset Alzheimer’s disease by beta-secretase cleavage within the secretory pathway. Nat Med 1:1291–1296. doi:10.​1038/​nm1295-1291 PubMedCrossRef
18.
Zurück zum Zitat Prihar G, Verkkoniem A, Perez-Tur J, Crook R, Lincoln S, Houlden H, Somer M, Paetau A, Kalimo H, Grover A, Myllykangas L, Hutton M, Hardy J, Haltia M (1999) Alzheimer disease PS-1 exon 9 deletion defined. Nat Med 5:1090. doi:10.1038/13383 PubMedCrossRef Prihar G, Verkkoniem A, Perez-Tur J, Crook R, Lincoln S, Houlden H, Somer M, Paetau A, Kalimo H, Grover A, Myllykangas L, Hutton M, Hardy J, Haltia M (1999) Alzheimer disease PS-1 exon 9 deletion defined. Nat Med 5:1090. doi:10.​1038/​13383 PubMedCrossRef
19.
Zurück zum Zitat Ning A, Cui JZ, To E, Hsiao Ashe K, Matsubara JA (2008) Amyloid beta deposits lead to retinal degeneration in a mouse model of alzheimer disease. Invest Ophthalmol Vis Sci Ning A, Cui JZ, To E, Hsiao Ashe K, Matsubara JA (2008) Amyloid beta deposits lead to retinal degeneration in a mouse model of alzheimer disease. Invest Ophthalmol Vis Sci
20.
Zurück zum Zitat Shimazawa M, Inokuchi Y, Okuno T, Nakajima Y, Sakaguchi G, Kato A, Oku H, Sugiyama T, Kudo T, Ikeda T, Takeda M, Hara H (2008) Reduced retinal function in amyloid precursor protein-over-expressing transgenic mice via attenuating glutamate-N-methyl-d-aspartate receptor signaling. J Neurochem 107:279–290. doi:10.1111/j.1471-4159.2008.05606.x PubMedCrossRef Shimazawa M, Inokuchi Y, Okuno T, Nakajima Y, Sakaguchi G, Kato A, Oku H, Sugiyama T, Kudo T, Ikeda T, Takeda M, Hara H (2008) Reduced retinal function in amyloid precursor protein-over-expressing transgenic mice via attenuating glutamate-N-methyl-d-aspartate receptor signaling. J Neurochem 107:279–290. doi:10.​1111/​j.​1471-4159.​2008.​05606.​x PubMedCrossRef
23.
Zurück zum Zitat Ida N, Hartmann T, Pantel J, Schroder J, Zerfass R, Forstl H, Sandbrink R, Masters CL, Beyreuther K (1996) Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J Biol Chem 271:22908–22914. doi:10.1074/jbc.271.37.22908 PubMedCrossRef Ida N, Hartmann T, Pantel J, Schroder J, Zerfass R, Forstl H, Sandbrink R, Masters CL, Beyreuther K (1996) Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J Biol Chem 271:22908–22914. doi:10.​1074/​jbc.​271.​37.​22908 PubMedCrossRef
24.
Zurück zum Zitat Buxbaum JD, Gandy SE, Cicchetti P, Ehrlich ME, Czernik AJ, Fracasso RP, Ramabhadran TV, Unterbeck AJ, Greengard P (1990) Processing of Alzheimer beta/A4 amyloid precursor protein: modulation by agents that regulate protein phosphorylation. Proc Natl Acad Sci USA 87:6003–6006. doi:10.1073/pnas.87.15.6003 PubMedCrossRef Buxbaum JD, Gandy SE, Cicchetti P, Ehrlich ME, Czernik AJ, Fracasso RP, Ramabhadran TV, Unterbeck AJ, Greengard P (1990) Processing of Alzheimer beta/A4 amyloid precursor protein: modulation by agents that regulate protein phosphorylation. Proc Natl Acad Sci USA 87:6003–6006. doi:10.​1073/​pnas.​87.​15.​6003 PubMedCrossRef
25.
Zurück zum Zitat Culvenor JG, Henry A, Hartmann T, Evin G, Galatis D, Friedhuber A, Jayasena UL, Underwood JR, Beyreuther K, Masters CL, Cappai R (1998) Subcellular localization of the Alzheimer’s disease amyloid precursor protein and derived polypeptides expressed in a recombinant yeast system. Amyloid 5:79–89PubMed Culvenor JG, Henry A, Hartmann T, Evin G, Galatis D, Friedhuber A, Jayasena UL, Underwood JR, Beyreuther K, Masters CL, Cappai R (1998) Subcellular localization of the Alzheimer’s disease amyloid precursor protein and derived polypeptides expressed in a recombinant yeast system. Amyloid 5:79–89PubMed
26.
Zurück zum Zitat Fodero-Tavoletti MT, Smith DP, McLean CA, Adlard PA, Barnham KJ, Foster LE, Leone L, Perez K, Cortes M, Culvenor JG, Li QX, Laughton KM, Rowe CC, Masters CL, Cappai R, Villemagne VL (2007) In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. J Neurosci 27:10365–10371. doi:10.1523/JNEUROSCI.0630-07.2007 PubMedCrossRef Fodero-Tavoletti MT, Smith DP, McLean CA, Adlard PA, Barnham KJ, Foster LE, Leone L, Perez K, Cortes M, Culvenor JG, Li QX, Laughton KM, Rowe CC, Masters CL, Cappai R, Villemagne VL (2007) In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. J Neurosci 27:10365–10371. doi:10.​1523/​JNEUROSCI.​0630-07.​2007 PubMedCrossRef
27.
Zurück zum Zitat Culvenor JG, McLean CA, Cutt S, Campbell BC, Maher F, Jakala P, Hartmann T, Beyreuther K, Masters CL, Li QX (1999) Non-Abeta component of Alzheimer’s disease amyloid (NAC) revisited. NAC and alpha-synuclein are not associated with Abeta amyloid. Am J Pathol 155:1173–1181PubMed Culvenor JG, McLean CA, Cutt S, Campbell BC, Maher F, Jakala P, Hartmann T, Beyreuther K, Masters CL, Li QX (1999) Non-Abeta component of Alzheimer’s disease amyloid (NAC) revisited. NAC and alpha-synuclein are not associated with Abeta amyloid. Am J Pathol 155:1173–1181PubMed
28.
Zurück zum Zitat Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, Collins F, Treanor J, Rogers G, Citron M (1999) Beta-secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286:735–741. doi:10.1126/science.286.5440.735 PubMedCrossRef Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, Collins F, Treanor J, Rogers G, Citron M (1999) Beta-secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286:735–741. doi:10.​1126/​science.​286.​5440.​735 PubMedCrossRef
29.
Zurück zum Zitat Holsinger RM, McLean CA, Beyreuther K, Masters CL, Evin G (2002) Increased expression of the amyloid precursor beta-secretase in Alzheimer’s disease. Ann Neurol 51:783–786. doi:10.1002/ana.10208 PubMedCrossRef Holsinger RM, McLean CA, Beyreuther K, Masters CL, Evin G (2002) Increased expression of the amyloid precursor beta-secretase in Alzheimer’s disease. Ann Neurol 51:783–786. doi:10.​1002/​ana.​10208 PubMedCrossRef
31.
Zurück zum Zitat Evin G, Zhu A, Holsinger RM, Masters CL, Li QX (2003) Proteolytic processing of the Alzheimer’s disease amyloid precursor protein in brain and platelets. J Neurosci Res 74:386–392. doi:10.1002/jnr.10745 PubMedCrossRef Evin G, Zhu A, Holsinger RM, Masters CL, Li QX (2003) Proteolytic processing of the Alzheimer’s disease amyloid precursor protein in brain and platelets. J Neurosci Res 74:386–392. doi:10.​1002/​jnr.​10745 PubMedCrossRef
Metadaten
Titel
Amyloid precursor protein processing and retinal pathology in mouse models of Alzheimer’s disease
verfasst von
R. Michael Dutescu
Qiao-Xin Li
Jonathan Crowston
Colin L. Masters
Paul N. Baird
Janetta G. Culvenor
Publikationsdatum
01.09.2009
Verlag
Springer-Verlag
Erschienen in
Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 9/2009
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-009-1060-3

Weitere Artikel der Ausgabe 9/2009

Graefe's Archive for Clinical and Experimental Ophthalmology 9/2009 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Die Verwendung von Ophthalmika in der Schwangerschaft und Stillzeit stellt immer eine Off-label-Anwendung dar. Ein Einsatz von Arzneimitteln muss daher besonders sorgfältig auf sein Risiko-Nutzen-Verhältnis bewertet werden. In der vorliegenden …

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Vitrektomie Originalie

Die endogene Endophthalmitis ist eine hämatogen fortgeleitete, bakterielle oder fungale Infektion, die über choroidale oder retinale Gefäße in den Augapfel eingeschwemmt wird [ 1 – 3 ]. Von dort infiltrieren die Keime in die Netzhaut, den …

Bakterielle endogene Endophthalmitis

Vitrektomie Leitthema

Eine endogene Endophthalmitis stellt einen ophthalmologischen Notfall dar, der umgehender Diagnostik und Therapie bedarf. Es sollte mit geeigneten Methoden, wie beispielsweise dem Freiburger Endophthalmitis-Set, ein Keimnachweis erfolgen. Bei der …

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Die bestmögliche Wundheilung der Kornea, insbesondere ohne die Ausbildung von lichtstreuenden Narben, ist oberstes Gebot, um einer dauerhaften Schädigung der Hornhaut frühzeitig entgegenzuwirken und die Funktion des Auges zu erhalten.   

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.